Hearscape
← Companies
Company

TRPHARM

Company-level hearing-loss landscape profile across checked programs, evidence quality, modalities, indications, and open data checks.

All ProgramsTherapeuticsDevices
Open filtered programs
Programs
1
linked to organization
Strong Evidence
0
0 status confirmed
Details Checked
1
0 open data checks
Company / Institution Links
1 / 0
industry vs non-industry records
Competitive Density
3
Pipeline Velocity
70
Completion Signal
0

Programs by Stage

Expanded Access1

Trial / Program Status

Active1

Modality Mix

Small Molecule1

Indication Coverage

Cisplatin-Induced Hearing Loss1
Hearing Loss1
Ototoxicity1

Program Types

Therapeutic1

Population Tags

cisplatin-ototoxicity1
expanded-access1
hepatoblastoma1
pediatric1

Strong-Evidence Records

0 records
No strong-evidence records are linked to this organization yet.

Checked Records With Caveats

1 checked · 0 open checks
TRPHARM sodium thiosulfate compassionate use program
Details checked
Small MoleculeExpanded AccessActive

Intravenous sodium thiosulfate access program for protection from cisplatin-induced hearing loss in children with standard-risk hepatoblastoma.

Data checks: expanded-access-program, split-from-mixed-sodium-thiosulfate-record